TRPV1 and Fabry disease: To summarize, our results illustrated that EA and antagonists and EA + antagonists increased gastrointestinal motility and decreased the expression of PAR2, PKC, TRPV1, CGRP, SP, and c-fos downstream of PAR2/PKC pathway in FD rats, thus alleviating VH, though no significant superposition effect between antagonists and EA + antagonists was documented.